Addex Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Addex Therapeutics Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.
Executive BD thesis
Addex Therapeutics presents a practical BD-screening case because its returned pipeline contains 31 records and the deal search returned 7 transaction records. The lead returned asset is ADX-71149, associated with 5-HT2A receptor x mGluR2 and Anxiety Disorders, Schizophrenia, Panic Disorder, at Phase 2. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.
The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | ADX-71149 | Addex Therapeutics Ltd. | Phase 2 | Pipeline record: 5-HT2A receptor x mGluR2; Anxiety Disorders, Schizophrenia, Panic Disorder. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery | Phase 2 asset with 5-HT2A receptor x mGluR2 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 2 | Dipraglurant | Addex Pharma SA | Phase 3 | Pipeline record: mGluR5; Dyskinesia, Drug-Induced, Parkinson Disease, Benign Essential Blepharospasm. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Addex And Janssen End Partnership; Epilepsy Candidate ADX71149 Rights Returned To Addex | Phase 3 asset with mGluR5 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 3 | NTX-253 | Addex Therapeutics Ltd. | Phase 1 | Pipeline record: M4 receptor; Schizophrenia. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Addex And Indivior Select Clinical Candidates From GABAB Positive Allosteric Modulator Research Collaboration | Phase 1 asset with M4 receptor exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 4 | Baclofen | Addex Therapeutics Ltd. | Preclinical | Pipeline record: GABAB receptor; Chronic cough. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery | Preclinical asset with GABAB receptor exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 5 | INDV-1000 | Addex Therapeutics Ltd. | Preclinical | Pipeline record: target not returned; Substance Abuse. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Addex And Janssen End Partnership; Epilepsy Candidate ADX71149 Rights Returned To Addex | Preclinical asset with undisclosed target exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2025-04-30 | Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery | Active | disclosed: false |
| 2025-04-17 | Addex And Janssen End Partnership; Epilepsy Candidate ADX71149 Rights Returned To Addex | Terminated | milestone_payment: 152.236; disclosed: true |
| 2024-08-27 | Addex And Indivior Select Clinical Candidates From GABAB Positive Allosteric Modulator Research Collaboration | Active | total_amount: 330; disclosed: false |
The most relevant returned precedent is: Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery (2025-04-30). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.
Financial capacity and partnering pressure
- CODEXIS, INC. - 2024 Quarterly report: CODEXIS, INC. - 2024 Quarterly report LIQUIDITY AND CAPITAL RESOURCES In addition to our existing cash and cash equivalents, short-term investments and revenue generated through our existing operations, we are eligible to earn milestone and other contingent payments for the achievement of defined collaboration objectives under our collaboration agreements. Our ability to earn these milestone and contingent payments and the timing of achieving these milestones is primarily dependent upon the outcome of our collaborators’ research and development activities and is uncertain at this time. We have historically experienced negative cash flows from operations as we continue to invest in key technology development projects and improvements to our CodeEvolver technology platform, develop and comme
- REGENXBIO Inc. - 2022 Annual report: REGENXBIO Inc. - 2022 Annual report Liquidity and Capital Resources Sources of Liquidity As of December 31, 2022, we had cash, cash equivalents and marketable securities of $565.2 million, which were primarily derived from the sale of our common stock, license and royalty revenue and the monetization of our Zolgensma royalty stream. We expect that our cash, cash equivalents and marketable securities as of December 31, 2022, will enable us to fund our operating expenses and capital expenditure requirements, and are sufficient to meet our financial commitments and obligations, for at least the next 12 months from the date of this report, based on our current business plan. Our recent sources of liquidity include the following events and transactions: • Effective in November 2021, we entered
Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether Addex Therapeutics is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.
Recent events and outreach timing
- No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.
Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.
IP and diligence risk screen
The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.
Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.
Recommended outreach sequence
- Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
- Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
- Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
- Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
- Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.
Bottom line
Addex Therapeutics merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate ADX-71149, confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
